{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:34:27Z","timestamp":1768818867146,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4505-4","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T11:43:50Z","timestamp":1533037430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023"],"prefix":"10.1186","volume":"18","author":[{"name":"for the Japanese Gynecologic Oncology Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadahiro","family":"Shoji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Kigawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Itamochi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Kamiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsutaro","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"4505_CR1","first-page":"459","volume":"70","author":"S Nakaji","year":"2012","unstructured":"Nakaji S, Umeda T, Takahashi I, Matsuzaka M, Iwane K. Epidemiological features of ovarian cancer in Japan and the world. Nihon Rinsho. 2012;70:459\u201364.","journal-title":"Nihon Rinsho"},{"key":"4505_CR2","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1053\/j.seminoncol.2006.03.011","volume":"33","author":"RF Ozols","year":"2006","unstructured":"Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33:S3\u201311.","journal-title":"Semin Oncol"},{"key":"4505_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419\u201325.","journal-title":"J Clin Oncol"},{"key":"4505_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","volume":"16","author":"S Pignata","year":"2015","unstructured":"Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol. 2015;16:561\u20138.","journal-title":"Lancet Oncol"},{"key":"4505_CR5","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","volume":"22","author":"M Markman","year":"2004","unstructured":"Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22:3120\u20135.","journal-title":"J Clin Oncol"},{"key":"4505_CR6","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473\u201383.","journal-title":"N Engl J Med"},{"key":"4505_CR7","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039\u201345.","journal-title":"J Clin Oncol"},{"key":"4505_CR8","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302\u20138.","journal-title":"J Clin Oncol"},{"key":"4505_CR9","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1158\/1078-0432.CCR-09-3100","volume":"16","author":"A Bagri","year":"2010","unstructured":"Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico LA, et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res. 2010;16:3887\u2013900.","journal-title":"Clin Cancer Res"},{"key":"4505_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.critrevonc.2011.09.006","volume":"83","author":"F Bellati","year":"2012","unstructured":"Bellati F, Napoletano C, Gasparri ML, Ruscito I, Marchetti C, Pignatti S, et al. Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms. Crit Rev Oncol Hematol. 2012;83:35\u201346.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4505_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, \u00d6sterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29\u201337.","journal-title":"Lancet Oncol"},{"key":"4505_CR12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(14)70439-5","volume":"15","author":"G von Minckwitz","year":"2014","unstructured":"von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1269\u201378.","journal-title":"Lancet Oncol"},{"key":"4505_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.cllc.2011.05.002","volume":"12","author":"C Gridelli","year":"2011","unstructured":"Gridelli C, Bennouna J, de Castro J, Dingemans AM, Griesinger F, Grossi F, et al. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial. Clin Lung Cancer. 2011;12:407\u201311.","journal-title":"Clin Lung Cancer"},{"key":"4505_CR14","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2217\/fon.14.75","volume":"10","author":"AA Brandes","year":"2014","unstructured":"Brandes AA, Mason W, Pichler J, Nowak AK, Gil M, Saran F, et al. Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy? Future Oncol. 2014;10:1137\u201345.","journal-title":"Future Oncol"},{"key":"4505_CR15","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928\u201336.","journal-title":"Lancet Oncol"},{"key":"4505_CR16","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","volume":"26","author":"A Grothey","year":"2008","unstructured":"Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26:5326\u201334.","journal-title":"J Clin Oncol"},{"key":"4505_CR17","unstructured":"Avastin\u00ae Prescribing Information. Genentech, Inc. Revised 05\/2015. \n                    http:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf\n                    \n                  . Accessed 7 July 2015."},{"key":"4505_CR18","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","volume":"25","author":"SA Cannistra","year":"2007","unstructured":"Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25:5180\u20136.","journal-title":"J Clin Oncol"},{"key":"4505_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ygyno.2010.01.011","volume":"118","author":"DL Richardson","year":"2010","unstructured":"Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab? Gynecol Oncol. 2010;118:47\u201351.","journal-title":"Gynecol Oncol"},{"key":"4505_CR20","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ygyno.2010.11.009","volume":"120","author":"JL Tanyi","year":"2011","unstructured":"Tanyi JL, McCann G, Hagemann AR, Coukos G, Rubin SC, Liao JB, et al. Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol. 2011;120:464\u20139.","journal-title":"Gynecol Oncol"},{"key":"4505_CR21","unstructured":"Common Toxicity Criteria, Version 2.0 Published Date April 30, 1999. \n                    http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcv20_4-30-992.pdf\n                    \n                  . Accessed 2 Dec 2015."},{"key":"4505_CR22","unstructured":"Gemzar Injection (R) [package insert]. Kobe: Eli Lilly Japan K.K.; 2013. \n                    http:\/\/www.info.pmda.go.jp\/go\/pack\/4224403D1030_1_19\/"},{"key":"4505_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10456-013-9334-0","volume":"16","author":"G Bocci","year":"2013","unstructured":"Bocci G, DiPaolo A, Danesi R. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis. 2013;16:481\u201392.","journal-title":"Angiogenesis"},{"key":"4505_CR24","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrclinonc.2010.120","volume":"7","author":"RD Baird","year":"2010","unstructured":"Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol. 2010;7:575\u201382.","journal-title":"Nat Rev Clin Oncol"},{"key":"4505_CR25","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","volume":"15","author":"W ten Bokkel Huinink","year":"1997","unstructured":"ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183\u201393.","journal-title":"J Clin Oncol"},{"key":"4505_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/028418602320404998","volume":"41","author":"P Rosenberg","year":"2002","unstructured":"Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol. 2002;41:418\u201324.","journal-title":"Acta Oncol"},{"key":"4505_CR27","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312\u201322.","journal-title":"J Clin Oncol"},{"key":"4505_CR28","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811\u20138.","journal-title":"J Clin Oncol"},{"key":"4505_CR29","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2009.04.026","volume":"114","author":"W Meier","year":"2009","unstructured":"Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, et al. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum\/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie ovarian Cancer study group (AGO-OVAR). Gynecol Oncol. 2009;114:199\u2013205.","journal-title":"Gynecol Oncol"},{"key":"4505_CR30","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.ejca.2009.05.016","volume":"45","author":"I Vergote","year":"2009","unstructured":"Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer. 2009;45:2324\u201332.","journal-title":"Eur J Cancer"},{"key":"4505_CR31","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","volume":"28","author":"BJ Monk","year":"2010","unstructured":"Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107\u201314.","journal-title":"J Clin Oncol"},{"key":"4505_CR32","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","volume":"30","author":"N Colombo","year":"2012","unstructured":"Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2012;30:3841\u20137.","journal-title":"J Clin Oncol"},{"key":"4505_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/annonc\/mdt515","volume":"25","author":"C Fotopoulou","year":"2014","unstructured":"Fotopoulou C, Vergote I, Mainwaring P, Bidzinski M, Vermorken JB, Ghamande SA, et al. Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Ann Oncol. 2014;25:160\u20135.","journal-title":"Ann Oncol"},{"key":"4505_CR34","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1200\/JCO.2009.23.1811","volume":"27","author":"SA Cannistra","year":"2009","unstructured":"Cannistra SA. Phase II trials in Journal of Clinical Oncology. J Clin Oncol. 2009;27:3073\u20136.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4505-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4505-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4505-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T23:05:58Z","timestamp":1564527958000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4505-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4505"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4505-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]},"assertion":[{"value":"16 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional review board approval has been obtained from each participating center. A full list of the ethics committees for each institution is provided in the Supplementary Information. All patients will be required to provide signed informed consent. This trial will be conducted according to the International Conference on Harmonization Guidelines for Good Clinical Practice, the Ethical Guideline for Medical and Health Research involving Human Subjects and applicable local laws and regulations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"T.Sh. has received honoraria for lectures and manuscript writing\/editing from Chugai Pharmaceutical. S. Ko., J.K., H.T., H.I., S. Ka, and T.H. have received honoraria for lectures from Chugai Pharmaceutical. H.F. and T.Su. have received honoraria for lectures and research grant from Chugai Pharmaceutical. K.K. declares that he has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"771"}}